UC San Diego researchers have launched a first-in-human Phase I clinical trial to assess the safety and efficacy of a gene therapy to deliver a key protein into the brains of persons with Alzheimer’s disease or Mild Cognitive Impairment, a condition that often precedes full-blown dementia.
Researchers at University of California San Diego School of Medicine identified new therapeutic targets for gastrointestinal stromal tumors (GISTs) that could lead to new treatment options for patients.
UC San Diego researchers report that individual immune response to SARS-CoV-2 may be limited by a set of variable genes that code for cell surface proteins essential for the adaptive immune system. The finding may help explain why COVID-19 immunity varies by individual.
UC San Diego researchers will inject harmless virus carrying a restorative gene into participants’ brains, where earlier animal studies suggest it may slow, prevent or reverse progression of the neurological disorder
The Department of Surgery announces four new division chair appointments, effective immediately. The organizational changes will advance state-of-the-art technologies, drive innovative surgical techniques to improve patient outcomes, and foster translational and patient centered research.
Gastrointestinal stromal tumors (GISTs) are a subtype of cancers known as sarcomas. GIST is the most common type of sarcoma with approximately 5,000 to 6,000 new patient cases annually in the United States. GIST cannot be cured by drugs alone, and targeted therapies are only modestly effective,...
No patients admitted to the UC Davis Medical Center tested positive for the flu this entire season, and experts credit flu vaccines, masking and social distancing with averting a possible “twindemic” of influenza and COVID-19.
Computational studies suggest a set of genes that regulate immune response help determine robustness and durability of neutralizing antibodies to virus
